Liang Su
- Biomedical Engineering top 10%
- Infectious Diseases top 5%
- Molecular Biology
- Materials Chemistry
- Biomaterials top 10%
- Topics
- COVID-19 Clinical Research Studies (3 papers)SARS-CoV-2 and COVID-19 Research (2 papers)Metabolomics and Mass Spectrometry Studies (2 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Liang Su
22 papers receiving 915 citations
Peers
Comparison fields: 5 of 117
- Biomedical Engineering 287
- Infectious Diseases 245
- Molecular Biology 215
- Materials Chemistry 188
- Biomaterials 154
Countries citing papers authored by Liang Su
This map shows the geographic impact of Liang Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang Su more than expected).
Fields of papers citing papers by Liang Su
This network shows the impact of papers produced by Liang Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang Su. The network helps show where Liang Su may publish in the future.
Co-authorship network of co-authors of Liang Su
This figure shows the co-authorship network connecting the top 25 collaborators of Liang Su. A scholar is included among the top collaborators of Liang Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liang Su. Liang Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 8 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 10 | |
| 6 | 1 | |
| 7 | 2 | |
| 8 | 253 | |
| 9 | 64 | |
| 10 | 3 | |
| 11 | 29 | |
| 12 | 6 | |
| 13 | 31 | |
| 14 | 22 | |
| 15 | 10 | |
| 16 | Quantification of a New Anti-Cancer Molecule MJC13 Using a Rapid, Sensitive, and Reliable Liquid Chromatography-Tandem Mass Spectrometry Method. | 4 |
| 17 | 16 | |
| 18 | 6 | |
| 19 | Risk analysis of avian influenza virus H5N1 subtype infection in different occupation groups | 2 |
| 20 | 31 |
About Liang Su
Liang Su is a scholar working on Infectious Diseases, Hepatology and Radiation, having authored 25 papers that have together received 922 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Metabolomics and Mass Spectrometry Studies (2 papers). The work is most often cited by research in Infectious Diseases (245 citations), Biomaterials (154 citations) and Obstetrics and Gynecology (86 citations). Liang Su has collaborated with scholars based in China and United States. Frequent co-authors include Dong Liang, Anil K. Sood, Min Zhou, Junjie Li, Chun Li, Xiang Ma, Zhongfa Zhang, Chun Yang, Pengfei Bian and Yanqin Liu. Their work appears in journals such as ACS Nano, PLoS ONE and Chemical Engineering Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.